Validation of the ACH2.0 and of the effectiveness of the proposed ACH2.0-based iAβ depletion therapy would justify a major effort to develop operative BACE1 and BACE2 activators, or other suitable iAβ-depleting agents, as potential preventive and curative AD and AACD drugs. This evidence concerns the gene BACE2 and Alzheimer disease.